Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Guerrero Murillo, Mercedes
  • dc.contributor.author Marchese, Domenica, 1986-
  • dc.contributor.author Heyn, Holger
  • dc.contributor.author Menéndez, Pablo
  • dc.date.accessioned 2025-01-22T07:23:45Z
  • dc.date.available 2025-01-22T07:23:45Z
  • dc.date.issued 2024
  • dc.description.abstract The impact of phenotypic, clonal, and functional heterogeneity of chimeric antigen receptor (CAR)-T cells on clinical outcome remains understudied. Here, we integrate clonal kinetics with transcriptomic heterogeneity resolved by single-cell omics to interrogate cellular dynamics of non-transduced (CARneg) and transduced (CARpos) T cells, in the infusion product (IP) and at the CAR-T cell expansion peak in five B cell acute lymphoblastic leukemia (B-ALL) patients treated with CD19CAR-T cells (varni-cel). We identify significant differences in cellular dynamics in response to therapy. CARpos T cells at IP of complete response patients exhibit a significantly higher CD4:CD8 ratio, validated in a larger cohort B-ALL patients (n = 47). Conversely, at the expansion peak, there is a clonal expansion of CD8+ effector memory and cytotoxic T cells. Cytotoxic CARpos γδ-T cells expansion correlates with treatment efficacy validated in a cohort of B-ALL (n = 18) and diffuse large B cell lymphoma (DLBCL) patients (n = 58). Our data provide insights into the complexity of T cell responses following CAR-T cell therapy and suggest drivers of immunotherapy response.
  • dc.description.sponsorship Research in P.M./C.B. laboratory was supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466, ERC-PoC-101100665), H2020 (101057250-CANCERNA), the Fight Kids Cancer Foundation (Cure2MLL project), the Spanish Research Agency (AEI) (PID2022-142966OB-I00 funded by MCIN/AEI/10.13039/501100011033; FEDER Funds; CPP2021-008508, CPP2021-008676, and CPP2022-009759 funded by MICIU/AEI/10.13039/501100011033; and the European Union NextGenerationEU/PRTR), Ayudas Merck de Investigación from Health Merck Foundation, the Spanish Association Against Cancer (AECC, PRYGN234975MENE), and the ISCIII-RICORS within the Next Generation EU program (Plan de Recuperación, Transformación y Resilencia). Additional funding was provided to C.B. by AECC (PRYGN211192BUEN), the Uno Entre Cien Mil Foundation, AIE (MINECO PLE2021-007518), Deutsche José Carreras Leukämie-Stiftung (DJCLS/02R/2023), and the Health Institute Carlos III (ISCIII/FEDER, PI20/00822 and PI24/00763).
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Guerrero-Murillo M, Rill-Hinarejos A, Trincado JL, Bataller A, Ortiz-Maldonado V, Benítez-Ribas D, et al. Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias. Cell Rep Med. 2024 Nov 19;5(11):101803. DOI: 10.1016/j.xcrm.2024.101803
  • dc.identifier.doi http://dx.doi.org/10.1016/j.xcrm.2024.101803
  • dc.identifier.issn 2666-3791
  • dc.identifier.uri http://hdl.handle.net/10230/69230
  • dc.language.iso eng
  • dc.publisher Elsevier
  • dc.relation.ispartof Cell Rep Med. 2024 Nov 19;5(11):101803
  • dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/957466
  • dc.relation.projectID info:eu-repo/grantAgreement/EC/HE/101100665
  • dc.relation.projectID info:eu-repo/grantAgreement/EC/HE/101057250
  • dc.relation.projectID info:eu-repo/grantAgreement/ES/3PE/PID2022-142966OB-I00
  • dc.rights © 2024 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
  • dc.subject.other Cèl·lules B--Tumors
  • dc.title Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion